CYDY (CytoDyn) Forward Dividend Yield %: 0.00% (As of Jun. 29, 2026)


CYDY CytoDyn Inc CYDY
28 GF Score
Price $0.25
! 1 Warning Sign
View Full Analysis

What is CytoDyn Forward Dividend Yield %?

CytoDyn CYDY +0.49% 28 Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus rates CYDY with a GF Score™ of 28/100. The stock has 1 warning sign investors should review. Among 145 Biotechnology companies, CytoDyn ranks worse than 689654.48% on this metric.

As of today (2026-06-29), the Forward Annual Dividend Yield of CytoDyn is 0.00%.

As of today (2026-06-29), the Trailing Annual Dividend Yield of CytoDyn is 0.00%.

CYDY's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

CytoDyn's Dividends per Share for the three months ended in Feb. 2026 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

CytoDyn  (OTCPK:CYDY) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

CytoDyn Forward Dividend Yield % Related Terms

CYDY vs VSTM, IRD, PALI: Forward Dividend Yield % Comparison

For the Biotechnology subindustry, CytoDyn's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoDyn Forward Dividend Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoDyn's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where CytoDyn's Forward Dividend Yield % falls into.


CYDY
28GF Score
CytoDyn Inc CYDY
Forward Dividend Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CytoDyn Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

What does a Forward Dividend Yield % of 0.00% mean?
CytoDyn (CYDY) has a Forward Dividend Yield % of 0.00% as of Jun. 29, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CytoDyn and its competitors. According to the industry distribution chart, CytoDyn ranks #999999 out of 145 companies in the Biotechnology industry.
Is CytoDyn's Forward Dividend Yield % too high?
CytoDyn's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, CytoDyn ranks #999999 out of 145 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytoDyn has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does CytoDyn's Forward Dividend Yield % compare to VSTM and IRD?
According to the Biotechnology industry distribution chart, CytoDyn ranks #999999 out of 145 companies for Forward Dividend Yield %. This places CytoDyn in the lower half of its industry. The industry median Forward Dividend Yield % is 1.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Biotechnology company?
The median Forward Dividend Yield % among Biotechnology companies is 1.51, based on 145 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on CytoDyn and its competitors. For the Biotechnology industry, the median Forward Dividend Yield % is 1.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytoDyn's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytoDyn stock overvalued right now?
CytoDyn (CYDY) has a current Forward Dividend Yield % of 0.00%. The current Forward Dividend Yield % is 0.00%. CytoDyn's overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For CytoDyn (CYDY), the current Forward Dividend Yield % is 0.00% as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CytoDyn Business Description

Other Exchanges 296:Germany
Address 1111 Main Street, Suite 660, Vancouver, WA, USA, 98660
CytoDyn Inc is a USA-based clinical-stage biotechnology company that focuses on the clinical development and potential commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The product candidate is PRO 140, which is a class of HIV therapy called entry inhibitors that block HIV from entering into and infecting certain cells. The company emphasizes exploring opportunities for clinical applications for PRO 140 involving the CCR5 (C-C chemokine receptor type 5) receptor, other than HIV-related treatments, such as inflammatory conditions, autoimmune diseases, and cancer.
28GF Score

Get the complete analysis for CYDY

Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.25
Price